Next-generation CAR-T and engineered T-cell immunotherapy
Strategic Profile
The company offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. Analysts initiated coverage with a $12.00 per share valuation in March 2026, positioning Estrella as a potential next-generation CAR-T innovator following recent multi-billion-dollar value creation demonstrated by Arcellx and its acquisition by Gilead Sciences.
Cyborg Score Rationale
The lead EB103 program shows encouraging Phase I STARLIGHT-1 data including a 100% complete response rate at Month 1 in the high-dose cohort (5 evaluable patients) and no Grade 3+ cytokine release syndrome reported. However, the company faces liquidity constraints—Estrella received a Nasdaq Non-Compliance Notice in January 2026—and the sample size remains extremely small.
Top Insights
Phase 1/2 STARLIGHT-1 study showed 100% complete response rate at dose level 2 despite approximately 80% of patients meeting high-risk disease criteria.
In Phase I (n=9), no treatment-related serious adverse events were reported and all cytokine release syndrome events were Grade 1–2.
Closed an $8.0 million registered direct offering and concurrent private placement in January 2026.
Collaborative agreement with Eureka and Imugene Limited for development of solid tumor treatments using Imugene's CF33-CD19t in conjunction with EB103.